How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

100 results for

Symlin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Comparison of Closed-loop Operation After Morning Meal With and Without Carbohydrate Counting

syndrome or cardiac surgery. Pregnancy. Severe hypoglycemic episode within two weeks of screening. • Medication likely to affect with the interpretation of the results: Prandase, Victoza, Byetta and Symlin Known or suspected allergy to the trial products or meal contents. Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator. Failure to comply with team's recommendations (e.g. not willing to eat snack

2012 Clinical Trials

42. Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM

. Has a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions: Hepatic disease Renal disease Gastrointestinal disease Pulmonary disease Organ transplantation Chronic infection (e.g., tuberculosis, human immunodeficiency virus, hepatitis B virus, or hepatitis C virus) Is currently treated or has been previously treated with SYMLIN/pramlintide or has (...) participated in a SYMLIN/pramlintide clinical study within 3 months of Visit 1 (Screening). Has any clinically significant laboratory findings or medical history that may affect successful completion of the study and/or personal well-being Has donated blood within 2 months or is planning to donate blood during the study. Has had a major surgery or a blood transfusion within 2 months Has received any investigational drug within 1 month Has known allergies or hypersensitivity to any component of study

2012 Clinical Trials

43. Improving Diabetes Outcomes Through Lifestyle Change (IDOLc)Study

(liraglutide), Bydureon (exenatide extended release), or Symlin (pramlintide) Must not be pregnant or planning pregnancy in the next year Must not be currently seeing a dietitian or participating in a weight loss program Must not have had a weight change of more than 5 pounds in the previous 3 months Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided

2012 Clinical Trials

44. Medtronic Treat to Range (TTR) Closed-Loop Control

; Subject has taken oral or injectable corticosteroids within the last 30 days; Current use of oral/inhaled Glucocorticoids Cystic fibrosis Inpatient psychiatric treatment in the past 6 months for either the subject or the subject's primary care giver (i.e., parent or guardian) Use of non-insulin medications that may affect blood glucose (eg Symlin), Systolic blood pressure >140 on screening; Diastolic blood pressure >90 on screening History of seizure or loss of consciousness in the last 6 months

2011 Clinical Trials

45. Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature

prescription drugs Subject is currently abusing alcohol Subject is using pramlintide (Symlin) at time of screening Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator Subject has elective surgery planned that requires general anesthesia during the course of the study Subject is a shift worker with working hours between 10pm and 8am. Subject has a sickle cell disease, hemoglobinopathy

2011 Clinical Trials

46. Pramlintide Combined With Model Predictive Control Algorithm

For females, not currently known to be pregnant An understanding of the protocol and a willingness to follow it HbA1c between 7 and 9% Normal renal function (determined utilizing the comprehensive metabolic panel at screening with the Modification of Diet in Renal Disease (MDRD) formula and defined by estimated Glomerular Filtration Rate (eGFR) of ≥60 ml/min/1.73 m2. Hematocrit >36 (females); >38 (males) Exclusion Criteria: Known hypersensitivity to SYMLIN or any of its components, including metacresol

2011 Clinical Trials

47. Insulin pump

, the system may function as an . Insulin pumps are being used for infusing pramlintide (brand name Symlin, or synthetic ) with insulin for improved compared to insulin alone. Dual hormone insulin pumps that infuse either insulin or . In event of hypoglycemia, the glucagon could be triggered to increase the blood glucose. This would be particularly valuable in a closed loop system under the control of a glucose sensor. The , currently in clinical trials for FDA approval, is a recently developed device

Full Text available with Trip Pro

2012 Wikipedia

48. Amylin

clinical study. The study combined metreleptin, a version of the human hormone leptin, and pramlintide, which is Amylin’s diabetes drug Symlin, into a single obesity therapy. Finally, a recent proteomics study showed that human amylin shares common toxicity targets with (Abeta), providing evidence that type 2 diabetes and Alzheimer's disease share common toxicity mechanisms. Pharmacology [ ] A synthetic analog of human amylin with proline substitutions in positions 25, 26 and 29, or pramlintide (brand

2012 Wikipedia

49. The Effects of a Pre-packaged, Portion Controlled Meal Plan on Type 2 Diabetes and Glycemic Control: A Comparison Study

to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Type 2 diabetic men and non-pregnant or non-lactating women between the ages of 21 to 75 BMI ≥ 25 and ≤ 50 Subjects must be willing to comply with all study-related procedures Participant with screening HbA1C ≥ 6.5 and <12.0. Exclusion Criteria: Use of Byetta (exenatide) or Symlin (pramlintide acetate) for diabetic control< 6 months. Participants must be stable on all other

2010 Clinical Trials

50. Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 37 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Exenatide (Byetta) Vs Pramlintide (Symlin): Role in Post-prandial Hyperglycemia Study Start Date : August 2009 Actual Primary Completion Date : August 2016 Actual Study Completion Date : December 2016 Resource links provided (...) by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Pramlintide + Insulin Group These kids will get Pramlintide (Symlin) along with insulin before breakfast and supper. Drug: Pramlintide Start at 15 mcg capped at 60 mcg before breakfast and supper subcutaneously for 4 months Other Name: Symlin Experimental: Exenatide + Insulin Group This group will get Exenatide(Byetta) along with insulin before breakfast

2010 Clinical Trials

51. Closed Loop System With Pramlintide Versus Exenatide

: January 4, 2011 Last Update Posted: February 20, 2018 Last Verified: February 2018 Keywords provided by Rubina Heptulla, Albert Einstein College of Medicine: Closed loop type 1 diabetes Symlin Byetta diabetes insulin insulin pump Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus, Type 1 Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases Insulin Exenatide Pramlintide Hypoglycemic Agents

2010 Clinical Trials

52. Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus

as well as on the ability of the immunocompromised host to fight infections. The investigators hypothesize that the addition of Pramlintide (Symlin) to the management of patients with PTDM would help patients with post-transplant diabetes attain better control at the critical time of titration of immunosuppressive regimens. The primary objective of this proposal is to improve glycemic control of diabetes with Pramlintide in patients with post-transplant diabetes at 3 and 6 months of therapy. Condition

2010 Clinical Trials

53. OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy

of a GLP-1 agonist or pramlintide (Symlin) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01182493 Sponsors and Collaborators Medtronic Diabetes Investigators Layout table for investigator information Principal Investigator: Ohad Cohen, MD Chaim Sheba

2010 Clinical Trials

54. A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension

with any of the following treatment excluded medications: Any exposure to exenatide (BYETTA®, exenatide once weekly, or exenatide suspension), liraglutide (Victoza®), or any GLP-1 receptor agonist Any DPP-IV inhibitor, sulfonylurea (SU), or rosiglitazone (Avandia®) within 3 months prior to study start Alpha glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®) within 30 days prior to study start Insulin within 2 weeks prior to study start, or for more than 1 week within 3 months

2010 Clinical Trials

55. Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

excluded medications for more than 1 week within the 3 months prior to study start, or have taken any of the following excluded medications within 1 month prior to study start: Insulin Alpha-glucosidase inhibitors (e.g., Glyser® [miglitol] or Precose® [acarbose]) Meglitinides (e.g., Prandin® [repaglinide] or Starlix® [nateglinide]) Avandia® (rosiglitazone) Dipeptidyl peptidase (DPP)-4 inhibitors (e.g., Januvia™ [sitagliptin], Galvus® [vildagliptin], Onglyza™ [saxagliptin]) Symlin® (pramlintide acetate

2009 Clinical Trials

56. Pramlintide in Adolescents With Type 1 Diabetes

Primary Completion Date : December 2009 Actual Study Completion Date : December 2009 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: 1 Symlin Subcutaneous injection of pramlintide prior to each meal with reduction of mealtime bolus insulin Drug: pramlintide subcutaneous injection (15 mcg initial dose)prior to meals Other Name: Symlin No Intervention: 2 Usual Regimen Usual

2009 Clinical Trials

57. Blood Sugar Response to Commercial Nutritional Supplements in Patients With Type 2 Diabetes

anti-diabetic agents which are non-insulin secretatgogues, i.e. Metformin and/or Pioglitazone Able to give informed consent Expected to be in the DC metropolitan for the duration of the study Fasting blood glucose between 70 and 250 mg/dl Exclusion Criteria: Patients with type 2 diabetes mellitus treated with insulin secretagogues (sulfonylurea and non-sulfonylurea), pramlintide (Symlin), GLP-1 analogs (Byetta), insulin, or alpha-glycosidase inhibitors A1c under 7.0% or over 10.0% Fasting blood

2009 Clinical Trials

58. A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

, or pramlintide (SYMLIN®) within 30 days prior to study start Insulin within 2 weeks prior to study start or for more than 1 week within 3 months prior to study start Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption Prescription or over-the-counter weight loss medications within 3 months prior to study start Contacts and Locations Go to Information from the National Library

2009 Clinical Trials

59. 6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes

with acetaminophen (paracetamol)-containing medications Serum creatinine > 2.0mg/dL at screening Serum ALT or AST greater than 3x upper limit of normal for the patient's age and gender, at screening Hemoglobin < 10g/dL, or platelet count less than 100,000/cu mm, at screening Treatment with any pharmacologic anti-hyperglycemic oral agent for more than 3 months at any time Treatment with any non-insulin antihyperglycemic medication (eg, Symlin®) for the 3 months prior to screening Treatment with systemic

2009 Clinical Trials

60. Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes

Able to speak, read, and write English Exclusion Criteria: On oral, inhaled or pre-mixed insulin On Symlin BMI > 35 kg/m2 Pregnant or intends to become pregnant during the course of the study Severe unexplained hypoglycemia that required emergency treatment over the past 3 months History of hemoglobinopathies Diagnosis of anemia HbA1C greater than 12% Post-renal transplantation, currently undergoing dialysis, creatinine of >1.5mg/dl or a calculated creatinine clearance of <50 mL/min. Have extensive

2009 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>